SCHEMBL391130

SCHEMBL391130

COC(=O)CC(N)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
CYP2C9 P11712 3/20 0.45
MEN1 O00255 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
GABBR2 O75899 3/20 0.44
GABBR1 Q9UBS5 3/20 0.44
LMNA P02545 2/20 0.44
CYP3A4 P08684 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
NFKB1 P19838 1/20 0.44
DRD3 P35462 1/20 0.44
BLM P54132 1/20 0.44
CYP1A2 P05177 1/20 0.44
THRB P10828 1/20 0.44
TSHR P16473 1/20 0.44
ADRB2 P07550 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1294954 1.00 L3MBTL1 (0.46) L3MBTL1CYP2C9MEN1CYP2D6CYP2C19
SCHEMBL3658423 1.00 L3MBTL1 (0.46) L3MBTL1CYP2C9MEN1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL391129 0.98 L3MBTL1 (0.44) L3MBTL1CYP2C9MEN1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL389435 0.98 L3MBTL1 (0.44) L3MBTL1CYP2C9MEN1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL391605 0.98 L3MBTL1 (0.44) L3MBTL1CYP2C9MEN1CYP2D6CYP2C19
SCHEMBL13802839 0.88 RAB9A (0.56) L3MBTL1MEN1KMT2AMAPTRAB9A
SCHEMBL23673364 0.84 ESR1 (0.46) CYP2C9CYP2D6CYP2C19MAPTRAB9A
SCHEMBL17167378 0.84 ALDH1A1 (0.44) L3MBTL1CYP2C19MAPTRAB9ALMNA
SCHEMBL8298418 0.84 MAPT (0.45) CYP2D6CYP2C19MAPTRAB9ALMNA
SCHEMBL5045992 0.84 ALDH1A1 (0.44) L3MBTL1CYP2C19MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 US disclosed
EP-3712128-A1 PHOTOCHEMICAL INTERMOLECULAR AMINATION METHOD Fundació Institut Català d'Investigació Química (ICIQ) (ES) 2020-09-23 EP disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 US disclosed
CN-107428720-B Substituted aminotriazoles as inhibitors of acid mammalian chitinase 昂科艾伦迪治疗法股份公司 2020-06-30 CN disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 US disclosed
EP-3233832-B1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS SA (PL) 2019-11-20 EP disclosed
EP-2083011-A1 PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2009-07-29 EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed
CN-101186612-A Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application TIANJIN HEMEI BIOLOG TECHNOLOG (CN) 2008-05-28 CN disclosed
US-7041667-B1 CCR5 modulators PFIZER, INC. (US) 2006-05-09 US disclosed
EP-1028125-B1 Dipeptide compounds having fungicidal activity and their agronomic use ISAGRO RICERCA SRL (IT) 2004-01-28 EP disclosed
US-6448228-B1 FUNCTIONALIZED OLIGOPEPTIDE HAVING HIGH FUNGICIDAL ACTIVITY; ONE OR TWO ALIPHATIC AMINO ACIDS SUCH AS VALINE, LEUCINE AND ISOLEUCINE, CONJUGATED TO ONE OR TWO AROMATIC AMINO ACIDS, SUCH AS PHENYL-GLYCINE, PHENYLALANINE AND BETA-PHENYLALANINE ISAGRO RICERCA S.R.L. (IT) 2002-09-10 US disclosed
EP-1028125-A1 Dipeptide compounds having fungicidal activity and their agronomic use Isagro Ricerca S.r.l. (IT) 2000-08-16 EP disclosed
EP-1013276-A1 Aminoazacycloalkanes as CCR5 modulators PFIZER INC. (US) 2000-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 L3MBTL1 1269/4885CYP2C9 4553/4885MEN1 730/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 L3MBTL1 1246/4885CYP2C9 4111/4885MEN1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.